1 / 96

ADVERSE DRUG EVENTS

ADVERSE DRUG EVENTS. Géza T. Terézhalmy, D.D.S., M.A. Professor and Dean Emeritus School of Dental Medicine Case Western Reserve University Cleveland, Ohio. Adverse Drug Events.

audrey-campbell
Télécharger la présentation

ADVERSE DRUG EVENTS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ADVERSE DRUG EVENTS Géza T. Terézhalmy, D.D.S., M.A. Professor and Dean Emeritus School of Dental Medicine Case Western Reserve University Cleveland, Ohio

  2. Adverse Drug Events • Clinicians and patients both acknowledge the major role played by drugs in modern health care Terezhalmy

  3. Adverse Drug Events Terezhalmy

  4. Adverse Drug Events • There are no “absolutely” safe biologically active therapeutic agents Terezhalmy

  5. Adverse Drug Events • Therapeutic agents seldom exert their beneficial effects without also causing adverse drug events Terezhalmy

  6. Adverse Drug Events • OHCP should be aware of the spectrum of drug-induced events and should be actively involved both in monitoring for and reporting such events Terezhalmy

  7. Adverse Drug Events • Etiology and epidemiology • 75 % of office visits to general medical practitioners and internists are associated with the initiation or continuation of pharmacotherapy • 3 to 11 % of hospital admissions are attributed to adverse drug events • 0.3 to 44 % of hospitalizations are complicated by adverse drug events Terezhalmy

  8. Adverse Drug Events • Etiology and epidemiology • The FDA has the most rigorous approval requirements in the world • Clinical trials cannot and are not expected to uncover every potential adverse drug event • Pre-marketing study populations generally include 3,000 to 4,000 subjects • Only adverse events, which occur more frequently than 1 in 1,000 will be observed • Detecting an adverse event with a incidence of 1 in 10,000 would require a study population of 30,000 Terezhalmy

  9. Adverse Drug Events • Etiology and epidemiology • Classification of adverse drug events • Type A reactions • Associated with the administration of therapeutic dosages of a drug (exception: drug overdose) • Usually predictable and avoidable • Responsible for most adverse drug events • Overdose • Cytotoxic reactions • Drug-drug interactions • Drug-food interactions • Drug-disease interactions Terezhalmy

  10. Adverse Drug Events • Etiology and epidemiology • Classification of adverse drug events • Type B reactions • Generally independent of dose • Rarely predictable or avoidable • While they are uncommon, they are often among the most serious and potentially life threatening • Idiosyncratic reactions • Immunologic/allergic reactions • Pseudo-allergic reactions • Teratogenic effects • Oncogenic effects Terezhalmy

  11. Adverse Drug EventsType A Reactions • Etiology and epidemiology • Cytotoxic effects • Formation of unstable or reactive metabolites related to some abnormality that interferes with normal metabolism and/or excretion of a drug • Two mechanisms • Oxidative pathway: the formation of electrophilic compounds, which bind covalently with cellular macromolecules • Reductive pathway: gives rise to intermediate compounds with an excess of electrons, which interact with O2 to produce free radicals Terezhalmy

  12. Adverse Drug EventsType A Reactions • Etiology and epidemiology • Drug-drug interactions • Two or more drugs administered at the same time or in close sequence • May act independently • May interact to  or  the magnitude or duration of action of one or more of the drugs • May interact to cause an unintended reaction • Drug-drug interactions all seem to have either a pharmacodynamic or a pharmacokinetic basis Terezhalmy

  13. Adverse Drug EventsType A Reactions • Etiology and epidemiology • Drug-drug interactions • Pharmacodynamic mechanisms • The intended or expected effect produced by a given plasma level of drug A is altered in the presence of drug B • Pharmacological drug-drug interactions • Physiological drug-drug interactions • Chemical drug-drug interactions • Drug-related receptor alterations Terezhalmy

  14. Adverse Drug EventsType A Reactions • Etiology and epidemiology • Drug-drug interactions • Pharmacodynamic mechanisms • Pharmacological drug-drug interactions • Drug A and drug B compete for the same receptor site and as a function of their respective concentrations either produce (an agonist) or prevent (an antagonist) an effect respectively • opioids vs. naloxone • acetylcholine vs. atropine • epinephrine vs. adrenergic receptor blocking agents Terezhalmy

  15. Adverse Drug EventsType A Reactions • Etiology and epidemiology • Drug-drug interactions • Pharmacodynamic mechanisms • Physiological interactions • Drug A and drug B interact with different receptor sites and either enhance each other’s action or produce an opposing effect via different cellular mechanisms • cholinergic agents vs diazepam • epinephrine vs. lidocaine • epinephrine vs. histamine Terezhalmy

  16. Adverse Drug EventsType A Reactions • Etiology and epidemiology • Drug-drug interactions • Pharmacodynamic mechanisms • Chemical interactions • Drug A interacts with drug B and prevents drug B from interacting with its intended receptor • protamine sulfate vs. heparin Terezhalmy

  17. Adverse Drug EventsType A Reactions • Etiology and epidemiology • Drug-drug interactions • Pharmacodynamic mechanisms • Drug-related receptor alterations • Drug A, when administered chronically, may either  or  the number of its own receptors or alter the adaptability of its receptors to physiological events • alpha1-adrenergic receptor agonists down-regulate their own receptors • beta1-adrenergic receptor antagonists up-regulate their own receptors Terezhalmy

  18. Adverse Drug EventsType A Reactions • Etiology and epidemiology • Drug-drug interactions • Pharmacokinetic mechanisms • Following concomitant administration, drug A may  or  the plasma level of drug B • Interactions affecting absorption • Interactions affecting distribution • Interactions affecting metabolism • Interactions affecting renal excretion • Interactions affecting biliary excretion Terezhalmy

  19. Adverse Drug EventsType A Reactions • Etiology and epidemiology • Drug-drug interactions • Pharmacokinetic mechanisms • Interactions affecting absorption • Drug A, by causing vasoconstriction, interferes with the systemic absorption of drug B • epinephrine  the systemic absorption of lidocaine • Drug A, by forming a complex with drug B, interferes with the systemic absorption of drug B • calcium  the systemic absorption of tetracycline Terezhalmy

  20. Adverse Drug EventsType A Reactions • Etiology and epidemiology • Drug-drug interactions • Pharmacokinetic mechanisms • Interactions affecting absorption • Drug A, by delaying gastric emptying, delays the systemic absorption of drug B, which is absorbed primarily in the small intestine • opioids delay the absorption of acetaminophen • Drug A, by elevating gastric pH, prevents the absorption of drug B (weak acids) • antacids  absorption of acetylsalicylic acid Terezhalmy

  21. Adverse Drug EventsType A Reactions • Etiology and epidemiology • Drug-drug interactions • Pharmacokinetic mechanisms • Interactions affecting distribution • Drug A ( a weak acid), by competing for plasma protein binding with drug B,  the plasma level of drug B • acetylsalicylic acid  the plasma level of many drugs Terezhalmy

  22. Adverse Drug EventsType A Reactions • Etiology and epidemiology • Drug-drug interactions • Pharmacokinetic mechanisms • Interactions affecting metabolism • Drug A, by  or  hepatic microsomal enzyme activity responsible for the metabolism of drug B,  or  plasma level of drug B respectively • H2-receptor antagonists  the plasma level of many drugs • macrolides, azole antifungal agents, ethanol (chronic use)  plasma level of many drugs Terezhalmy

  23. Adverse Drug EventsType A Reactions • Etiology and epidemiology • Drug-drug interactions • Pharmacokinetic mechanisms • Interactions affecting metabolism • Drug A, by  hepatic non-microsomal enzyme activity responsible for the metabolism of drug B,  the plasma level of drug B • MAO-inhibitors  the plasma level of benzodiazepines Terezhalmy

  24. Adverse Drug EventsType A Reactions • Etiology and epidemiology • Drug-drug interactions • Pharmacokinetic mechanisms • Interactions affecting metabolism • Drug A, by inhibiting the enzyme acetaldehyde dehydrogenize, interferes with the further metabolism of intermediate metabolites (oxidation products) of drug B • disulfuram and metronidazole interfere with the metabolism of ethanol Terezhalmy

  25. Adverse Drug EventsType A Reactions • Etiology and epidemiology • Drug-drug interactions • Pharmacokinetic mechanisms • Interactions affecting renal excretion • Drug A, which competes with drug B for the same excretory transport mechanisms in the proximal tubules,  the plasma level of drug B • acetylsalicylic acid and probenecid  the plasma level of penicillin and other weak acids Terezhalmy

  26. Adverse Drug EventsType A Reactions • Etiology and epidemiology • Drug-drug interactions • Pharmacokinetic mechanisms • Interactions affecting renal excretion • Drug A, by alkalizing the urine,  the plasma level of drug B • sodium bicarbonate  the plasma level of weak acids • Drug A, by acidifying the urine,  the plasma level of drug B • ammonium chloride  the plasma level of weak bases Terezhalmy

  27. Adverse Drug EventsType A Reactions • Etiology and epidemiology • Drug-drug interactions • Pharmacokinetic mechanisms • Interactions affecting biliary excretion • Drug A, by increasing bile flow and the synthesis of proteins, which function in biliary conjugation mechanisms,  the plasma level of drug B • Phenobarbital  the plasma level of many drugs • Drug A binds drug B, which undergoes extensive hepatic recirculation,  the plasma level of drug B • activated charcoal and cholestyramine  the plasma level of many drugs Terezhalmy

  28. Adverse Drug EventsType A Reactions • Etiology and epidemiology • Drug-food interactions • Most known drug-food interactions appear to be associated with pharmacokinetic mechanisms • Interactions affecting absorption • Nutrients may act as a mechanical barrier that prevents drug access to mucosal surfaces and  the rate of absorption of some drugs • Nutrients with high fatty acid content may actually  the rate of absorption of drugs with high lipid solubility Terezhalmy

  29. Adverse Drug EventsType A Reactions • Etiology and epidemiology • Drug-food interactions • Interactions affecting absorption • Chemical interactions between a drug and food component can result in the formation of inactive complexes and  the absorption of the drug • calcium  the absorption of tetracyclines • ferrous or ferric salts  the absorption of tetracyclines and fluoroquinolones • zinc  the absorption of fluoroquinolones Terezhalmy

  30. Adverse Drug EventsType A Reactions • Etiology and epidemiology • Drug-food interactions • Interactions affecting metabolism • Components of some nutrients can inhibit CYP450 isoenzymes and  the metabolism of some drugs • grapefruit juice  the metabolism of warfarin, benzodiazepines, and calcium-channel blocking agents Terezhalmy

  31. Adverse Drug EventsType A Reactions • Etiology and epidemiology • Drug-disease interactions • A drug prescribed for the treatment of one disease can adversely affect a different condition that has been generally well controlled • Pharmacodynamic mechanisms • Pharmacokinetic mechanisms Terezhalmy

  32. Adverse Drug EventsType A Reactions • Etiology and epidemiology • Drug-disease interactions • Pharmacodynamic mechanisms • Non-selective beta1-adrenergic receptor antagonists, prescribed for the treatment of chronic stable angina, hypertension, or cardiac arrhythmia can increase airway resistance by interacting with beta2-adrenergic receptors • induce asthma in susceptible patients Terezhalmy

  33. Adverse Drug EventsType A Reactions • Etiology and epidemiology • Drug-disease interactions • Pharmacodynamic mechanisms • Beta1-adrenergic receptor antagonists and calcium-channel blocking agents prescribed for the treatment of chronic stable angina, hypertension, or cardiac arrhythmia interacting with their own receptors • precipitate cardiac complications secondary to negative inotropism (decreased contractility), decreased nodal conductance, and peripheral vasodilatation (cardiac steal syndrome) in susceptible patients Terezhalmy

  34. Adverse Drug EventsType A Reactions • Etiology and epidemiology • Drug-disease interactions • Pharmacodynamic mechanisms • Beta1-adrenergic receptor antagonists can adversely affect carbohydrate metabolism and inhibit epinephrine-mediated hyperglycemic response to insulin • Increase the risk of hypoglycemia and mask some of its clinical manifestations in diabetic patients Terezhalmy

  35. Adverse Drug EventsType A Reactions • Etiology and epidemiology • Drug-disease interactions • Pharmacodynamic mechanisms • COX-1 inhibitors block cyclooxygenase-dependent prostaglandin and thrombaxane A2 synthesis • Exacerbate peptic ulcer disease and gastroesophageal reflux disease in susceptible patients Terezhalmy

  36. Adverse Drug EventsType A Reactions • Etiology and epidemiology • Drug-disease interactions • Pharmacodynamic mechanisms • Hypothyroidism •  sensitivity to CNS depressants in susceptible patients • Hyperthyroidism •  susceptibility to epinephrine-induced hypertension and cardiac arrhythmia Terezhalmy

  37. Adverse Drug EventsType A Reactions • Etiology and epidemiology • Drug-disease interactions • Pharmacokinetic mechanisms • Cardiac dysfunction •  metabolism and excretion of drugs • Hepatic dysfunction •  metabolism and biliary and renal excretion of drugs • Renal dysfunction •  hepatic metabolism and renal excretion of drugs Terezhalmy

  38. Adverse Drug EventsType B Reactions • Etiology and epidemiology • Idiosyncratic reactions • Drug metabolism is largely dominated by oxidation reactions catalyzed by the cytochrome P450 enzyme system • Genetic polymorphism is the primary factor responsible for inter-individual variability in response to drugs • Therapeutic consequences • intrinsic characteristics of the drug • importance of the deficient metabolic pathway • existence of alternative pathways Terezhalmy

  39. Adverse Drug EventsType B Reactions • Etiology and epidemiology • Allergic/immune reactions • In susceptible patients alkylation and/or oxidation of cellular macromolecules by drug metabolites can lead to the production of immunogens • Not related to the dose administered • Specificity to a given agent • Transferability by antibodies or lymphocytes • Recurrence when re-exposure to the offending drug occurs • Most reactions occur in young or middle aged adults • Drug allergy is twice a frequent in women than in man Terezhalmy

  40. Adverse Drug EventsType B Reactions • Etiology and epidemiology • Allergic/immune reactions • Type I (immediate) hypersensitivity Terezhalmy

  41. Adverse Drug EventsType B Reactions • Etiology and epidemiology • Allergic/immune reactions • Type II (cytotoxic) hypersensitivity Terezhalmy

  42. Adverse Drug EventsType B Reactions • Etiology and epidemiology • Allergic/immune reactions • Type III (immune-complex) hypersensitivity Terezhalmy

  43. Adverse Drug EventsType B Reactions • Etiology and epidemiology • Allergic/immune reactions • Type IV (delayed) hypersensitivity Terezhalmy

  44. Adverse Drug EventsType B Reactions • Etiology and epidemiology • Pseudoallergic reactions • Cannot be explained on an immunologic basis • Occur in patients who had no prior exposure to the drug • Certain medications directly activate mast cells through non-IgE-receptor pathways and initiate the release of bioactive substances • Other medications block the degradation of bioactive substances • Still other medications, by inhibiting the action of cyclooxygenase activity,  synthesis of lipoxygenase-dependent leukotrienes Terezhalmy

  45. Adverse Drug EventsType B Reactions • Etiology and epidemiology • Teratogenic/developmental effects • Teratogens are substances capable of causing physical or functional defects in the fetus in the absence of toxic effects in the mother • Teratogenic effects depend on the accumulation of a drug or its metabolite in the fetus at critical time periods • 3rd to 12th week of gestation Terezhalmy

  46. Adverse Drug EventsType B Reactions • Etiology and epidemiology • Oncogenic effects • Primary oncogenic effects • Produced by certain procarcinogenic drugs, which have been converted into carcinogens by polymorphic oxidative reactions • Reactive metabolites bind covalently to DNA • Secondary oncogenic effects • Therapeutic immunosuppression in the presence of infection with oncogenic viruses • HBV, HCV, CMV, HSV, HPV, and EMV • Pattern of cancer is different than in the general population Terezhalmy

  47. Adverse Drug Events Terezhalmy

  48. Adverse Drug Events • Clinical manifestations • Type A reactions • Primary (direct effects) or secondary (indirect effects) • Dose dependent • Exaggerations of direct effects • Multiple concurrent “side “ effects • Type B reactions • Primary (direct effects) or secondary (indirect effects) • Generally independent of the dose Terezhalmy

  49. Adverse Drug EventsType A Reactions • Clinical manifestations • Cytotoxic reactions Terezhalmy

  50. Adverse Drug EventsType A: Cytotoxic Reactions Terezhalmy

More Related